Hematologic Malignancies

$Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS$

Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS

By MedXY 01/19/2026

This Phase 1 study evaluates rogocekib, a novel CDC2-like kinase inhibitor, in patients with relapsed or refractory hematologic malignancies, reporting manageable safety and significant complete remission rates in AML and MDS cohorts, signaling a new frontier in splicing-targeted therapy.